ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ILMN Stock Price » ILMN Stock News

Illumina Share News

 Illumina (mm) Stock Price
ILMN Stock Price
 Illumina (mm) Stock Chart
ILMN Stock Chart
 Illumina (mm) Stock News
ILMN Stock News
 Illumina (mm) Company Information
ILMN Company Information
 Illumina (mm) Stock Trades
ILMN Stock Trades

Roche Sends Second Letter To Illumina Shareholders

ZURICH -(Dow Jones)- Roche Holding Holding AG (ROG.VX) Wednesday sent a second letter to shareholders of takeover target Illumina Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche's increased offer and vote for Roche's independent director nominees at the U.S. gene sequencing company's AGM later this month. MAIN FACTS: - Roche raised its offer to $51 per Illumina share on March 29. - Letter from Roche Chief Executive Severin Schwan says Illumina board has been unwilling to engage in meaningful discussions "despite our willingness to pay a substantial price for your shares." - "After Roche's multiple attempts to engage were rebuffed, we were left with no choice but to bring our offer directly to you, Illumina's shareholders, and provide you with the opportunity to act in your own financial interests," Schwan writes. - "At $51.00, the fiduciary responsibilities of the board and management of Illumina require engagement," Schwan writes. - " The best way for you, as a shareholder, to obtain value certainty today for your shares is to vote for engagement. Tender your shares into our offer and vote for Roche's independent director nominees and other proposals at the 2012 Illumina Annual Meeting to be held on 18 April 2012." - Illumina shares closed Tuesday up 0.6% at $52. -Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com

Stock News for Illumina (ILMN)
DateTimeHeadline
03/28/201719:07:03Statement of Changes in Beneficial Ownership (4)
03/23/201714:15:53Statement of Changes in Beneficial Ownership (4)
03/08/201719:59:00MLL Münchner Leukämielabor wählt IBM Watson und Illumina für For...
03/08/201716:34:00Le Munich Leukemia Laboratory lance avec IBM Watson et Illumina...
03/08/201703:52:00CORRECTING & REPLACING Munich Leukemia Laboratory Selects IBM...
03/08/201702:00:00Munich Leukemia Laboratory Selects IBM Watson & Illumina for...
03/07/201708:00:00OPKO Subsidiary GenPath Women’s Health Announces the Availability o...
03/01/201708:06:13Current Report Filing (8-k)
02/28/201709:30:00OPKO Health’s GeneDx Announces Participation in Illumina’s iHo...
02/28/201709:00:00Illumina Announces the iHope Network, an Expansion of Its iHope...
02/21/201713:21:21Current Report Filing (8-k)
02/21/201706:30:00Illumina to Webcast Live Presentation at the Cowen and Company...
02/20/201709:00:00Illumina Names John W. Thompson to Its Board of Directors, Bringing...
02/14/201710:54:35Statement of Ownership (sc 13g)
02/14/201706:10:26Annual Report (10-k)
02/13/201717:26:21Amended Statement of Ownership (sc 13g/a)
02/13/201708:33:01Current Report Filing (8-k)
02/10/201715:57:00Statement of Changes in Beneficial Ownership (4)
02/10/201715:34:03Amended Statement of Ownership (sc 13g/a)
01/31/201716:32:30Current Report Filing (8-k)

Illumina and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US